Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors

A Phase 1 Study of Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors

The purpose of this research study is to test the safety of chloroquine in combination with carboplatin and gemcitabine and see what effects (good and bad) it has on advanced solid tumors.

Also, the research study will be increasing the dose of chloroquine to find the highest dose of chloroquine that can be given in combination with carboplatin and gemcitabine without causing severe side effects.

Inclusion Criteria:

• Histologically confirmed diagnosis of a malignancy that is metastatic or unresectable and for which either standard curative measures do not exist or are no longer effective and carboplatin/gemcitabine is considered a reasonable treatment option whether first line or acceptable and approved combination therapy.
• Age >18 years of age.
• Performance status less than or equal 2 (Karnofsky >60%)
• Life expectancy of greater than 3 months.
• Adequate labs
• Measurable disease

Exclusion Criteria:

• Current treatment with any other investigational agents.
• Patients with untreated brain metastases
• History of allergic reaction attributed to compounds of similar chemical or biologic composition to chloroquine or other agents used in study.